Daniel M. Jorgensen

PolyMedix, Inc. engaged in developing first-in-class, small-molecule defensin-mimetics for the treatment of serious acute care conditions. The company was founded in 2002 and was headquartered in Radnor, PA.

Part of Finch Therapeutics Group, Inc., Finch Research & Development LLC provides biopharmaceutical services. The company is based in Cambridge, MA. Finch Research & Development was acquired by Finch Therapeutics, Inc. on October 23, 2017.

Centers for Disease Control and Prevention operates as a government health center. It helps to prevent and control infectious and chronic diseases, injuries, workplace hazards, disabilities and environmental health threats. It conducts research and investigations for its action oriented approach. The company was founded on July 1, 1946 and is located in Atlanta, GA.

Critical Path Institute is a nonprofit organization established in 2005 as a public and private partnership with the FDA's Critical Path Initiative program. The non-profit company is based in Tucson, AZ, and operates from Ireland with additional staff in multiple other locations. The company's mission is to catalyze the development of new approaches that advance medical innovation and regulatory science, accelerating the path to a healthier world. The company orchestrates the development of drug development tools through an innovative, collaborative approach to the sharing of data and expertise, and accelerate the pace and reduce the costs of medical product development by building consensus among the participating institutions. The company was founded in 2005 by Raymond L. Woosley, Glenn C. Rice. Daniel M. Jorgensen has been the CEO of the company since 2022.